A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer
To access this article, please choose from the options below
PII: S0169-5002(08)00575-8
doi:10.1016/j.lungcan.2008.11.002
© 2008 Elsevier Ireland Ltd. All rights reserved.
